Navigation Links
Newly Published Study Reveals Femara Improves Chances for Harder to,Treat Early Breast Cancer Relapse in Postmenopausal Women

h tamoxifen Femara also demonstrated a significant reduction in the risk of recurrence to the same breast (local recurrence), the other breast and to the lymph nodes (regional recurrence).

"Femara is the only aromatase inhibitor shown to significantly reduce the risk of distant metastases versus tamoxifen as initial adjuvant therapy in postmenopausal women with hormone-sensitive early breast cancer. This is particularly good news since we know that this type of recurrence significantly worsens the prognosis for these women," said Dr Andrew Wardley, study investigator and consultant medical oncologist at the Christie Hospital, Manchester, and the South Manchester University Hospitals NHS Trust.

The retrospective analysis also identified patients at higher risk of recurrence based on clinical and pathological disease characteristics. The results showed that patients with the highest risk of early recurrence had tumours larger than five centimetres, four or more positive nodes, positive oestrogen receptor status but negative progesterone status, grade three tumours and invasive disease. Notably, women with node positive disease, who are considered to be at a higher risk of recurrence, maintained this lower risk of relapse when treated with upfront Femara than with tamoxifen(1).

"These results provide the tip of the iceberg and for the bigger picture, physicians will be eagerly awaiting the results of the BIG 1-98 sequencing arms, which hope to indicate the optimal strategy for using Femara post surgery and are due to be ready for 2008. This is why Novartis has made a significant commitment to sponsor this important study", said Hugh O'Dowd, Business Unit Director, Novartis Oncology UK.

Notes to Editors

About BIG 1-98

BIG 1-98 is the only clinical trial that incorporates both a head-to-head comparison and a sequencing of Femara and tamoxifen as adjuvant treatment for postmenopausal women with hormone receptor positive breast can
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Velcade (bortezomib) for Injection Based Therapies Achieved Survival Rates as High as 100 Percent in Newly Diagnosed Multiple Myeloma Patients
2. Newly Published Data from Large Study Support Cardiovascular Safety of Avandia (Rosiglitazone Maleate)
3. Newly Published Data Demonstrates Superiority of Cipralex Over Duloxetine for Acute Treatment of Depression
4. Adding Thalidomide to Standard Therapy Improves Survival in Newly Diagnosed Multiple Myeloma Patients Over Age 75
5. New Analysis of Data from WHI Provides Reassurance With Respect to Coronary Heart Disease For Newly Menopausal Women Considering Hormone Therapy
6. ECOG Phase III Newly Diagnosed Multiple Myeloma Trial (E4A03) Reports Lenalidomide Plus Low-Dose Dexamethasone Suggests Survival Advantage for Patients with Multiple Myeloma
7. MRI Detects Cancers in the Opposite Breast of Women Newly Diagnosed with Breast Cancer
8. Nymox Announces Positive Results from Newly Completed Long-term Study of NX-1207 for Benign Prostatic Hyperplasia
9. Newly Released Canadian Data Links Vaccines with Pervasive Developmental Disorder
10. New Phase 3 Study Published in The Lancet Evaluates Efficacy and Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination Therapy in Treatment-Experienced Adults With HIV
11. New Proof of Genisteins Efficacy and Safety for Osteopenia and Osteoporosis Published in Annals of Internal Medicine
Post Your Comments:
(Date:12/24/2014)... 2014  Actavis plc (NYSE: ACT ... a complete response letter from the U.S. Food ... Application (NDA) for the fixed-dose combination (FDC) of ... Photo - http://photos.prnewswire.com/prnh/20130124/NY47381LOGO ... receipt of a complete response letter, Actavis remains ...
(Date:12/24/2014)... Dec. 24, 2014 Kinex Pharmaceuticals announced today ... at Roswell Park Cancer Institute. KX2-361 (KX02), ... that has shown potent inhibitory activity against a broad ... are resistant to Temozolomide (T98G), the most widely used ... well-established brain tumor mouse model, KX2-361 consistently clears brain ...
(Date:12/24/2014)... Dec. 24, 2014  Conkwest, Inc., the Natural ... proprietary Natural Killer (NK) cell-line platform, Neukoplast® (NK-92™) ... Patrick Soon-Shiong , NantWorks founder, physician scientist and ... to purchase approximately $48 million of the Company,s ... investment, he will be named Co-Chairman of the ...
Breaking Medicine Technology:Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 2Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 3Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 4Kinex Pharmaceuticals Announces First Patient Dosed with KX2-361 in a Phase 1 Clinical Study 2Kinex Pharmaceuticals Announces First Patient Dosed with KX2-361 in a Phase 1 Clinical Study 3Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 2Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 3Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 4Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 5
(Date:12/26/2014)... (PRWEB) December 26, 2014 Parker ... for the best in heating, cooling and plumbing ... 24 hour emergency services in 2014 with regard ... know that Arizona is known for its incredibly ... that understands the intricacies and details of a ...
(Date:12/25/2014)... (PRWEB) December 26, 2014 ... BambooFlooringChina.com combines beauty, strength and durability. Today, the ... promotion, which is valid until Jan. 30, 2015. ... grain of traditional hardwood. BambooFlooringChina.com is a well-known ... help consumers worldwide to find a reliable bamboo ...
(Date:12/25/2014)... 25, 2014 Product liability lawsuits filed ... recall ( http://www.consumerinjurylawyers.com/DePuy/ ) continue to move forward in ... Order issued in the U.S. District Court, Northern District ... an open conference on January 7, 2015, at the ... in West Palm Beach, Florida. The Conference is scheduled ...
(Date:12/25/2014)... Recently, Dylan Queen, a famous online company ... collection of discounted prom dresses, most of which are ... of the company, the promotion is valid until Jan. ... expand the UK market. , The prom dresses in ... and styles: A-line strapless, empire strapless chiffon, one shoulder, ...
(Date:12/25/2014)... 2014 BambooFlooringChina.com sells many bamboo products ... flooring. Today, the company announces big discounts on ... and colors. , BambooFlooringChina.com is the world’s leader in ... is valid until Jan. 20, 2015. , The bamboo ... with a natural thread. All the bamboo strips for ...
Breaking Medicine News(10 mins):Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 2Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 3Health News:BambooFlooringChina.com: click strand woven bamboo flooring promotion valid until Jan. 30, 2015. 2Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 2Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 3Health News:Dylan Queen: Cheap Prom Dresses for the UK Market 2Health News:Various Styles of Bamboo Mats in Many Colors from BambooFlooringChina.com 2
... on the Vine Varieties not Subject to Salmonella ... ... brand, and is North America,s largest grower of greenhouse,tomatoes, wants to let consumers ... US are not subject to the most recent June,7, 2008 Salmonella alert issued ...
... ST. LOUIS, June 9 ETHEX Corporation announced today,that ... sulfate 60 mg,extended release tablets (Lot No. 91762) due ... thickness. Oversized tablets may contain as much as,two times ... was,distributed by ETHEX Corporation under an "ETHEX" label between ...
... parasite, a team of researchers has been able to ... has thereby broken the cycle of infection during recent ... parasite through gene knock-out technol-ogy, a research team consisting ... Hopkins University, Baltimore, has prevented the parasite from going ...
... both genders over 25-year period , , MONDAY, June 9 ... arteries work just as well in women as in men, ... recent years, new research finds. , The study in the ... College of Cardiology is a marker in a fading ...
... Sen. Max Baucus,(D-MT), chair of the Senate ... bill that includes pharmacy-related provisions to provide ... claims and delay the,implementation of Medicaid reimbursement ... Roberts, RPh, executive vice president and CEO ...
... ALBANY, Ore., June 9 Synthetech, Inc. (OTC,Bulletin ... 2008 Dr. Gregory R.,Hahn will become Synthetech,s President ... has served as Synthetech,s President and Chief,Operating Officer. ... Dr.,Daniel T. Fagan, who will continue as Synthetech,s ...
Cached Medicine News:Health News:Consumers Can Purchase Majority of Tomato Varieties 2Health News:ETHEX Corporation Voluntarily Recalls a Single Lot of Morphine Sulfate 60 mg Extended Release Tablets Due to the Potential for Oversized Tablets 2Health News:ETHEX Corporation Voluntarily Recalls a Single Lot of Morphine Sulfate 60 mg Extended Release Tablets Due to the Potential for Oversized Tablets 3Health News:Researchers block transmission of malaria in animal tests 2Health News:Researchers block transmission of malaria in animal tests 3Health News:Artery-Opening Method Works Well in Women 2Health News:Artery-Opening Method Works Well in Women 3Health News:NCPA Statement on Sen. Baucus' Medicare Bill Inclusion of Solutions for Medicare and Medicaid Reimbursement Problems 2Health News:Synthetech Announces Appointment of Dr. Gregory R. Hahn as President and Chief Executive Officer 2Health News:Synthetech Announces Appointment of Dr. Gregory R. Hahn as President and Chief Executive Officer 3
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: